Kuma Partners

Kurma Partners is a prominent European venture capital firm based in Paris, specializing in healthcare and biotechnology investments. Founded in 2009, Kurma Partners has carved a niche in transforming cutting-edge scientific research into viable businesses. Their portfolio includes over 60 companies, with notable investments in Dynacure, Cardiologs, and IO Biotech. Focusing primarily on biotechnology, therapeutics, diagnostics, and health tech, Kurma Partners supports companies from early-stage seed funding to growth capital. They are particularly known for their deep collaboration with leading European research institutes, which helps them create startups based on groundbreaking scientific discoveries. This approach has resulted in the creation of more than 24 companies, many of which have become leaders in their fields. Geographically, Kurma Partners concentrates on Europe but has also made strategic investments in the United States. Their investment strategy includes both leading and participating in funding rounds, with typical investment sizes ranging from €1 million to €10 million, depending on the company's stage and needs. Kurma Partners' funds include the Kurma Biofund series and the Kurma Diagnostics funds, which emphasize innovative therapeutic and diagnostic solutions. The firm's leadership team boasts significant expertise, with key figures such as Thierry Laugel, Rémi Droller, and Sylvain Cascarino steering its strategic direction. They are actively involved in the portfolio companies, providing not just capital but also mentorship and industry connections. Kurma Partners is also committed to ESG principles, ensuring their investments align with ethical standards and contribute to sustainable development goals. For startups seeking investment, Kurma Partners recommends approaching them with a clear validation plan and leveraging their strong network of industry experts and entrepreneurs.